Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-11-01
1998-09-08
Eisenchenck, Frank C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 231, 4241841, A61K 4800, C12N 1512, C12N 1552
Patent
active
058045660
ABSTRACT:
The invention is directed to methods for introducing biologically active peptides into a host by administration of polynucleotides which operatively encode for the peptide of interest. In a preferred embodiment of the invention, a mammal is desensitized to an antigen, in particular an allergen, through administration to the mammal of polynucleotides which operatively encode the antigen. The antigen-encoding polynucleotides are administered to host tissues which have a high concentration of antigen presenting cells in them relative to other host tissues. The method is particularly useful in treating allergies because the allergen-encoding polynucleotides of the invention to induce tolerance while suppressing IgE antibody formation. Devices and compositions for use in the methods of the invention are also described.
REFERENCES:
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
Mader et al., PNAS, 1993, 90:5603.
Chien, "Mucosal Drug Delivery: Potential Routes for Noninvasive Systemic Administration," Novel Drug Delivery Systems, vol. 50, pp. 197-227.
Chien, "Transdermal Drug Delivery and Delivery Systems," Novel Drug Delivery Systems, vol. 50, pp. 301-380.
Chien, "Nasal Drug Delivery and Delivery Systems," Novel Drug Delivery Systems, vol. 50, pp. 229-268.
Sloan, "Use of Solubility Parameters from Regular Solution Theory to Describe Partitioning-Driven Processes," Prodrugs: Topical and Ocular Drug Delivery, vol. 53, pp. 179-204.
Tice, et al., "Parenteral Drug Delivery: Injectables," Treatise on Controlled Drug Delivery, pp. 315-339.
Chang, et al., "Nasal Drug Delivery," Treatise on Controlled Drug Delivery, pp. 423-463.
Been, et al., "One Binding Site Determines Sequence Specificity of Tetrahymena Pre-rRNA Self Splicing, Trans-Splicing, and RNA Enzyme Activity," Cell, vol. 47, 207-216, Oct. 24, 1986.
Gillies, et al., "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," Bio/Technology, vol. 7, Aug. 1989, pp. 799-804.
Ward, et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli, Nature, vol. 341, 12 Oct. 1989, pp. 544-546.
Wolff, et al., Conditions Affecting Direct Gene Transfer into Rodent Muscle In Vivo, BioTechniques vol. 11, No. 4 (1991), pp. 474-485.
Cohen, "Naked DNA Points Way to Vaccines," Science, vol. 259, 19 Mar. 1993, pp. 1691-1692.
Acsadi, et al., "Human dystrophin expression in mdx mice after intramusclular injection of DNA constructs," Nature, vol. 352, 29 Aug. 1991, pp. 815-818.
Wolff, et al., "Indirect Gene Transfer into Mouse Muscle in Vivo," Science, vol. 24, Mar. 1990, pp. 1465-1468.
Barr, et al., "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts," Science, vol. 254, Dec. 1991, pp. 1507-1512.
Ulmer, et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," Science, vol. 259, 19 Mar. 1993, pp. 1745-1748.
"The Ultimate Delivery System: Lectro Patch Instructions," Advertisement by General Medical Company.
Kaplan, et al., "Rational Immunotheraphy with Interleukin 2," Bio/Technology, vol. 10, Feb. 1992, pp. 157-162.
Caligiuri, et al., "Selective Modulation of Human Natural Killer Cells In Vivo After Prolonged Infusion of Low Dose Recombinant Interleukin 2," J. Clin. Invest., vol. 91, Jan. 1993, pp. 123-132.
Teppler, et al., "Prolonged Immunostimulatory Effect of Low-Dose Polyethylene Glycol Interleukin 2 in Patients with Human Immunodeficiency Virus Type 1 Infection," J. Exp. Med., vol. 177, Feb. 1993, 483-492.
Lotz, et al., Brief Definitive Report, J. Exp. Med., vol. 67, Mar. 1988, 1253-1258.
Robinson, et al., "Use of Direct DNA Inoculations to Elicit Protective Immune Responese," Journal of Cellular Biochemistry, Supp. 17D, 1993, p. 92.
Donohue, et al., "In Vivo Administration of Purified Jurkat-derived Interleukin 2 in Mice," Cancer Research, vol. 44, Apr. 1984, pp. 1380-1386.
Goldstein, et al., "Repetitive Weekly Cycles of Interleukin 2: Effect of Outpatient Treatment with a Lower Dose of Interleukin 2 . . . ," Cancer Research, vol. 49, pp. 6832-6839, Dec. 1, 1989.
Hefeneider, et al., "In Vivo Interleukin 2 Administration Augments the Generation of Alloreactive Cytolytic T Lymphocytes and Resident Natural Killer Cells," Journal of Immunlogy, vol. 130, No. 1, 1/83, 222/227.
Stribling, et al., "Aerosol gene delivery in vivo," Proc. Natl. Acad. Sci. USA, vol. 89, pp. 11277-11281 Dec. 1992.
Del Rey, et al., "Antidiabetic effects of interleukin 1," Proc. Natl. Acad. Sci. USA, vol. 86, pp. 5943-5947, Aug. 1989.
Shields, et al., "Calorie restriction suppresses subgenomic mink cytopathic focus-forming murine leukemia virus transcription and frequency . . . ," Proc. Natl. Acad. Sci. USA, vol. 88, pp. 11138-11142, Dec. 1991.
Tang, et al., "Genetic immunization is a simple method for eliciting an immune response," Nature, vol. 356, 12 Mar. 1992, pp. 152-154.
Gorman, et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells . . . ," Proc. Natl. Acad. Sci. USA, vol. 79, pp. 6777-6781, Nov. 1982.
Norton, et al., "Bacterial B-Galactosidase as a Marker of Rous Sarcoma Virus Gene Expression and Replication," Molecular and Cellular Biology, vol. 5, No. 2, Feb. 1985, pp. 281-290.
Krieg, et al., "Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs," Nucleic Acids Research, IRL Press Limited, vol. 12, No. 18, 1984, pp. 7057-7070.
Multi-Test, Lincoln Diagnostics, Inc., pp. 1-6.
Terr, "Allergy Desensitization," pp. 739-743.
Secrist, et al., "Allergen Immunotherapy Decreases Interleukin 4 Production in CD4+ T Cells from Allergic Individuals," J. Exp. Med., vol. 178, Dec. 1993, pp. 2123-2130.
Kemeny, et al., "CD8+ T cells in allergy," Allergy, 47:12-21, 1992.
Nakagawa, et al., "Immunotherapy of Allergic Diseases," Int. Arch. Allergy Immunol., 102:117-120 (1993).
Chua, et al., "Sequence Analysis of cDNA Coding for a Major House Dust Mite Allergen," J. Exp. Med., vol. 167, Jan. 1988, pp. 175-182.
Davis, et al., "Plasmed DNA Is Superior to Viral Vectors for Direct Gene Transfer into Adult Mouse Skeletal Muscle," Human Gene Therapy, 4:733-740 (1993).
Carson Dennis A.
Howell Meredith L.
Raz Eyal
Eisenchenck Frank C.
The Regents of the University of California
LandOfFree
Methods and devices for immunizing a host through administration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and devices for immunizing a host through administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and devices for immunizing a host through administration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1282288